CorrespondenceSildenafil for lung fibrosis and pulmonary hypertension
References (1)
Cited by (6)
Phosphodiesterase-5 inhibition: The molecular biology of erectile function and dysfunction
2005, Urologic Clinics of North AmericaCitation Excerpt :In this case, the nitroglycerin medication provides a nitric oxide agonist drive to blood vessels throughout the body, and concomitant inhibition of PDE5 could produce a life-threatening or fatal hypotensive event. Recent reports indicate that sildenafil shows promise in treatment of other maladies associated with vascular dysfunction; this includes pulmonary hypertension where the nitric oxide agonist production in the affected vessels is robust and, therefore, the PDE5 inhibitors can act effectively to elevate cGMP [8,84–88]. Studies in animal models also suggest a role for sildenafil in improved recovery from stroke [89,90] and blunting or reversal of cardiac hypertrophy [91].
Sildenafil: Emerging cardiovascular indications
2004, Annals of Thoracic SurgeryCitation Excerpt :In patients with congestive heart failure and erectile dysfunction, a recently published double-blind, placebo-controlled study showed that sildenafil was not only well tolerated and effective for erectile dysfunction but it also improved exercise capacity [59]. In addition to the classic primary pulmonary hypertension and pulmonary hypertension that results from cardiac disease, some benefit might also exist in pulmonary hypertension of relatively rare etiology [34, 60–71], or postoperative pulmonary hypertension, and difficult weaning problems in mechanical respiration [72–75]. The weaning of inhaled NO, which is often followed by a rebound phenomenon, might especially be an indication for sildenafil [73, 75].
Effect of sildenafil in primary pulmonary hypertension
2007, Pakistan Journal of Medical SciencesIdiopathic pulmonary fibrosis: A decade of progress
2006, Jornal Brasileiro de Pneumologia